I hope you never need this but Dr Rosenberg is the man I spoke of at the NIH who is curing widely metastatic melanoma patients who have had multiple multiple previous treatments with adoptive T cell therapy
From the NCI website:
Trial and Protocol Number
Melanoma
Phase II
Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of MART-1 Reactive Peripheral Blood Lymphocytes (PBL) With or Without High Dose Aldesleukin
NCI-12-C-0045, NCT01495572
Principal Investigator: Referral Contact:
Udai Kammula June A. Kryk
301-435-8606 1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma
NCI-11-C-0260, NCT01468818
Principal Investigator: Referral Contact:
Steven A. Rosenberg June A. Kryk
1-866-820-4505 (Toll Free) 1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase II Study of Tumor Infiltrating Lymphocytes Generated With Engineered Cells for Costimulation Enhancement in Patients With Metastatic Melanoma Following Lymphodepletion
NCI-11-C-0163, NCT01369875
Principal Investigator: Referral Contact:
Steven A. Rosenberg June A. Kryk
1-866-820-4505 (Toll Free) 1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I/II
A Phase I/II Study of IL-15 Administration Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen and Autologous Lymphocyte Transfer in Metastatic Melanoma
NCI-11-C-0170, NCT01369888
Principal Investigator: Referral Contact:
Steven A. Rosenberg June A. Kryk
1-866-820-4505 (Toll Free) 1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I/II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of CD8 Enriched Tumor Infiltrating Lymphocytes Genetically Engineered to Express IL-12
NCI-11-C-0011, NCT01236573
Principal Investigator: Referral Contact:
Steven A. Rosenberg June A. Kryk
1-866-820-4505 (Toll Free) 1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I
An Open-label, Multicenter, Single-arm, Phase I Dose-escalation With Efficacy Tail Extension Study of RO5185426 in Pediatric Patients With Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAF V600 Mutations
NCI-13-C-0064, NCT01519323
Principal Investigator: Referral Contact:
Melinda Merchant Pediatric Oncology
301-443-7955 301-496-4256
1-877-624-4878 (Toll free)
A Pilot Trial of the Combination of Vemurafenib With Adoptive Cell Therapy in Patients With Metastatic Melanoma
NCI-12-C-0114, NCT01585415
Principal Investigator: Referral Contact:
Steven A. Rosenberg June A. Kryk
1-866-820-4505 (Toll Free) 1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
No Phase
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI)
NCI-11-C-0123, NCT01319565
Principal Investigator: Referral Contact:
Steven A. Rosenberg June A. Kryk
1-866-820-4505 (Toll Free) 1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Trial and Protocol Number
Melanoma, Ocular (uveal)
Phase II
Phase II Study in Patients With Metastatic Ocular Melanoma Using a Non-myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Autologous Tumor-Infiltrating Lymphocytes With or Without High Dose Aldesleukin
NCI-13-C-0093, NCT01814046
Principal Investigator: Referral Contact:
Udai Kammula June A. Kryk
301-435-8606 1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov